Therefore, the beneficial effect of ibrutinib in combination with dexamethasone may partially be attributed to the ability of the BTK inhibitor to suppress dexamethasone-induced M2c polarization and an associated increase in CXCL13 in the MM niche. Here, BTK is linked to Miyoshi myopathy.